Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Trueblood Wealth Management LLC

Trueblood Wealth Management LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.2% in the third quarter, Holdings Channel reports. The institutional investor owned 10,886 shares of the medical equipment provider’s stock after selling 598 shares during the quarter. Trueblood Wealth Management LLC’s holdings in Lantheus were worth $1,195,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in LNTH. Daiwa Securities Group Inc. acquired a new position in Lantheus in the first quarter worth $1,269,000. Nordea Investment Management AB boosted its holdings in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after purchasing an additional 14,147 shares during the period. Hancock Whitney Corp boosted its holdings in Lantheus by 265.6% in the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after purchasing an additional 14,639 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new position in Lantheus in the second quarter worth $290,000. Finally, Pitcairn Co. boosted its holdings in Lantheus by 117.0% in the first quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock worth $521,000 after purchasing an additional 4,509 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

LNTH stock opened at $110.30 on Friday. The company has a market capitalization of $7.66 billion, a P/E ratio of 18.08 and a beta of 0.50. The company has a 50-day simple moving average of $107.32 and a 200 day simple moving average of $92.71. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.40 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Leerink Partners boosted their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Finally, B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.